Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)

NCT05605899 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT05605899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05605899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)
Lead sponsor
Kite, A Gilead Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 10, 2023
Completion date
March 31, 2031
Enrollment
300 (estimated)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk large b-cell lymphoma (lbcl)